Feature | October 14, 2013

Renal Denervation Market: Impact of Major Barriers Underestimated by Industry Experts

renal denervation, Symplicity

An illustration of how renal denervation therapy is delivered, in this case using a Medtronic Symplicity device.

October 14, 2013 — Since its debut in 2010, the renal denervation market has generated enthusiasm across the medical device industry with predictions that the market would reach more than $1 billion by 2020.  However, the impact of major barriers, which will slow down this growth, was essentially underestimated according to an analyst with research and consulting firm GlobalData.

According to Joseph Gregory, GlobalData's analyst covering surgical devices, one of the most pressing barriers is reimbursement. Renal denervation has been approved in Europe since 2010 but has only seen full reimbursement in Germany and Austria as of 2013.

“The various European-run health insurance agencies are not entirely convinced of the long-term safety and efficacy of the procedure due to the lack of available data from sophisticated clinical trials. Currently, procedures in these countries are either being funded out of pocket or by a portion of hospital budgets dedicated toward the use of novel technologies,” said Gregory.

The establishment of a new referral pattern is another significant hurdle for the renal denervation market. Patients typically see their primary care physician first, and once uncontrolled hypertension is diagnosed, their physicians refer them to a hypertension specialist or cardiologist who will then make a final referral for the procedure.

“Medical device companies which specialize in interventional cardiology products have strong, established relationships with cardiologists, but their network does not extensively breach this first line of referral from primary care physicians. Thus, the sales and marketing teams of renal denervation companies have the difficult job of developing this network from scratch,” said Gregory.

The current state of the clinical trial data will also constrain the market, according to Gregory. While company-sponsored studies have to date proven short-term safety and efficacy, there is still ambiguity with regards to device performance in the long term, as well as the degree of efficacy that can be achieved.

“Further, looking at long-term procedure outcomes for renal denervation, there is very limited data available, as the longest follow-up to date is just three years, from Medtronic’s open-label, non-randomized Symplicity HTN-1 study,” said Gregory. “Overall, taking into consideration the full impact of these and numerous other market barriers, it is doubtful that renal denervation will prove to be the next blockbuster in the medical device industry.”

For more information: www.globaldata.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init